89653-84-9

Upstream product

• 1466-76-8 2-6-dimethoxybenzoic acid 

Downstream Products

• 82935-49-7 2-<(N-ethyl-3,5-dibromo-2,6-dimethoxybenzamido)methyl>-1-ethylpyrrolidine 
• 125714-91-2 2,3,4-Tribrom-5-(3',5'-dibrom-2',6'-dimethoxyphenyl)-1H-pyrrol 
• 125734-67-0 2,3,4-Tribrom-5-(3',5'-dibrom-2'-hydroxy-6'-methoxyphenyl)-1H-pyrrol 
• 125714-90-1 2-(3',5'-Dibrom-2',6'-dimethoxyphenyl)-1H-pyrrol 
• 125714-89-8 1-(3',5'-Dibrom-2',6'-dimethoxyphenyl)-1,4-butandion 
• 73220-00-5 (+)-A 32508 
• 73220-02-7 (-)-A 32508 
• 125714-88-7 1-(3',5'-Dibrom-2',6'-dimethoxyphenyl)-3-(1'',3''-dioxan-2''-yl)-1-propanon 

Relevant academic research and scientific papers

Potential Neuroleptic Agents. 2,6-Dialkoxybenzamide Derivatives with Potent Dopamine Receptor Blocking Activities

A series of some novel N-(1-ethyl-2-pyrrolidinylmethyl)benzamides was synthesized and tested for dopamine receptor blockade in vivo by the ability to block the apomorphine syndrome in the rat.Several compounds were considerably more potent than sulpiride as dopamine receptor blockers and displayed low liability to induce extrapyramidal side effects (catalepsy) in the rat.The blockade of dopamine receptor activity in vivo was mainly confined to the levorotatory isomers having the S absolute configuration.The structure-activity relationships are discussed.

1-amidooctahydropyrido[2,1-c][1,4]oxazine compounds

The invention relates to the compounds of general formula STR1 in which R1, R2, R4, R5 and A are as defined in the description. their isomers, diastereoisomers, and enantiomers as well as their addition salts with a pharmaceutically acceptable inorganic or organic acid, and medicinal products containing the same which are usable for the treatment of psycho-behavioral disorders.